| __timestamp | BioCryst Pharmaceuticals, Inc. | Pharming Group N.V. |
|---|---|---|
| Wednesday, January 1, 2014 | 7461000 | 4042025 |
| Thursday, January 1, 2015 | 13047000 | 5279557 |
| Friday, January 1, 2016 | 11253000 | 8073913 |
| Sunday, January 1, 2017 | 13933000 | 44864073 |
| Monday, January 1, 2018 | 29514000 | 53488904 |
| Tuesday, January 1, 2019 | 37121000 | 65896361 |
| Wednesday, January 1, 2020 | 67929000 | 69968267 |
| Friday, January 1, 2021 | 118818000 | 92047281 |
| Saturday, January 1, 2022 | 159371000 | 131819000 |
| Sunday, January 1, 2023 | 213894000 | 87501000 |
Infusing magic into the data realm
In the dynamic world of biotechnology, understanding financial trends is crucial for investors and stakeholders. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent biotech companies: Pharming Group N.V. and BioCryst Pharmaceuticals, Inc., from 2014 to 2023.
BioCryst Pharmaceuticals has shown a remarkable increase in SG&A expenses, growing by approximately 2,800% over the decade. This surge reflects their aggressive expansion and investment in marketing and administrative capabilities. In contrast, Pharming Group N.V. experienced a more moderate increase of around 2,100%, indicating a steady yet strategic growth approach.
The year 2022 marked a peak for both companies, with BioCryst's expenses reaching their highest at 159 million, while Pharming Group's expenses peaked at 132 million. These trends highlight the evolving strategies and market positioning of these biotech giants, offering valuable insights for industry observers.
Selling, General, and Administrative Costs: Eli Lilly and Company vs Pharming Group N.V.
Pfizer Inc. or BioCryst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and BioCryst Pharmaceuticals, Inc.
Comparing SG&A Expenses: Viatris Inc. vs Pharming Group N.V. Trends and Insights
Who Optimizes SG&A Costs Better? Insmed Incorporated or BioCryst Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Pharming Group N.V.
Comparing SG&A Expenses: Pharming Group N.V. vs Xenon Pharmaceuticals Inc. Trends and Insights
Pharming Group N.V. vs HUTCHMED (China) Limited: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing ADMA Biologics, Inc. and BioCryst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Bausch Health Companies Inc. and BioCryst Pharmaceuticals, Inc.
Mesoblast Limited and BioCryst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared